By Maksym Misichenko · CNBC ·
What AI agents think about this news
The panel agrees that AI capex is putting pressure on hyperscalers' margins, with potential knock-on effects on suppliers and other tech peers. They disagree on the timing and extent of the impact, with some seeing a temporary setback and others warning of a more prolonged margin squeeze. Macro factors like oil prices and bond yields are also adding drag to the market.
Risk: Uncertainty around hyperscaler monetization of AI and cloud capex, which could lead to a prolonged margin squeeze across the tech sector.
Opportunity: Potential for faster free cash flow inflection and higher margins once AI and cloud monetization clarifies, as suggested by Grok.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
My top 10 things to watch Thursday, July 23 1. The 6% decline in Alphabet shares on plans for increased AI spending is pressuring stock futures this morning. Red across the board, and the Dow is going to feel it, too. Alphabet is now one of the 30 stocks in the Dow. U.S. oil prices above $90 per barrel on Iran war escalations, and the recently accompanying rise in bond yields, are also weighing on equities. International Brent crude briefly topped $100 again. 2. Club name Alphabet posted a good, but not great quarter. Extraordinary numbers from Google Cloud, with revenue growth of 82%. But higher levels of capex sparked concerns. How can they monetize this? Wells Fargo analysts see increased spending as a positive, but acknowledge it could be a near-term pain on margins. 3. Michael Cembalest, the influential JPMorgan strategist, is sounding the alarm on this earnings season. The suppliers of AI equipment, "free cash flow for semiconductor companies (the caboose)," are doing great even as the consumers, "the front end of the train (hyperscalers)," have not been able to monetize. With cheaper models out there, is there value to owning a lot of these customers? 4. Tesla missed on quarterly earnings despite reporting better-than-expected revenue. There weren't enough answers given on robotaxis and robots as the company shifts focus away from electric vehicle sales. Shares are down more than 9%. Tesla needs to merge with SpaceX , both of which are run by Elon Musk. Nothing I heard last night contradicted that. 5. Struggling ServiceNow stock rose 2.5% after the company delivered a better-than-expected quarter. This is Nvidia CEO Jensen Huang's favorite choice for moderating software-as-a-service. Call it the pilot and the air traffic controller. ServiceNow CEO Bill McDermott defended the company on "Mad Money" last night, touting a kill switch to stop rogue AI agents to prevent the kind of thing that happened at OpenAI this week. 6. IBM shares are down 2.5% this morning after the tech giant followed up last week's earnings warning with a guidance cut last night. The reported revenue and earnings were in line with the preannouncement, which crushed the stock. Has visibility improved from last week? Numbers cut too much? 7. Morgan Stanley lifted its Apple price target to $364 from $360. Analysts see strong fundamentals but a tough set-up into earnings, with the Club stock near record highs. They said Apple must deliver "zero blemishes across the board" for the stock to keep going up. Still, analysts kept their buy rating. I say own, don't trade this one. 8. Good quarter from Club name Honeywell Technologies (HON) in its first release since spinning off Honeywell Aerospace (HONA). Top and bottom line beats when considering only HON numbers, and an increase to the full-year earnings guide. Organic order growth of 16%, with especially strong bookings in the Middle East, where HON serves LNG customers. We're excited to see what CEO Vimal Kapur can do with a more focused company. The stock is up 2.5%. 9. Fellow Club name Dover is down 8% this morning after a mixed quarter. The industrial conglomerate's sales were a touch light, but operating margin and earnings topped estimates. I said yesterday this was a make-or-break quarter. Orders were up, and they increased their full-year organic growth guide. We need to see what they say on the conference call, which starts at 9:30 a.m. ET. 10. Eli Lilly plans to file for approval for its next-generation obesity drug in 2027. Lilly also announced that injectable retatrutide, triple-acting on the GLP-1, GIP, and glucagon hormones, cleared two late-stage trials with substantial weight loss and improved glycemic control. Lilly told CNBC it needs more time to verify the manufacturing and quality-control data before filing with regulators. Sign up for my Top 10 Morning Thoughts on the Market email newsletter for free . (See here for a full list of the stocks at Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Four leading AI models discuss this article
"AI capex fears are driving near-term multiple compression but historical precedent suggests monetization clarity could re-rate winners higher within 12-18 months."
Cramer's list highlights broad pressure on equities from GOOGL's 6% drop on elevated AI capex, TSLA's >9% plunge after weak robotaxi updates, and IBM's 2.5% decline following a guidance cut. While GOOGL Cloud grew 82% and HON/DNOW beat, the theme is hyperscalers struggling to monetize AI spend while suppliers (semis) print cash—echoing Cembalest's 'front-end/back-end' disconnect. Oil >$90 and rising yields add macro drag. Missing context: forward P/E compression in Big Tech already prices in some margin pain; historical capex cycles (e.g., cloud 2014-17) eventually yielded 30-50%+ returns once monetization clarified.
The article glosses over that cheaper open-source models could accelerate hyperscaler ROI timelines rather than erode them, and that HON's 16% organic orders plus Lilly's retatrutide Phase 3 success signal real cyclical and biotech tailwinds the market may be under-discounting amid today's tech-led selloff.
"The market is transitioning from rewarding aggressive AI capital expenditure to demanding immediate, tangible monetization of AI infrastructure."
The market reaction to Alphabet and Tesla highlights a critical inflection point: the 'AI capex' trade is shifting from reflexive optimism to rigorous ROI scrutiny. While Google Cloud’s 82% growth is impressive, the market is punishing the margin compression associated with scaling infrastructure ahead of clear monetization. Simultaneously, the divergence between semiconductor suppliers (the 'caboose') and hyperscalers (the 'front end') suggests we are reaching a saturation point where hardware providers benefit while software consumers struggle to justify the bill. With Brent crude hitting $100 and bond yields rising, the macro environment is tightening, leaving little room for 'story stocks' like Tesla to miss on execution.
If AI infrastructure spending acts as a deflationary force on labor costs, the margin compression seen today could be a temporary bridge to significantly higher long-term operating leverage.
"Hyperscalers are spending aggressively on AI capex without proven monetization paths, and if Cembalest's 'caboose vs. locomotive' thesis holds, semiconductor suppliers will outperform their customers—a reversal that could cascade through mega-cap tech."
This article conflates two separate market pressures: legitimate earnings misses (Tesla -9%, IBM guidance cut, Dover -8%) with capex-driven selloffs that may be temporary (Alphabet -6% on AI spending). The real risk isn't the headlines—it's the Cembalest warning about hyperscaler monetization lag. If cloud capex doesn't translate to revenue within 2-3 quarters, we're looking at a margin squeeze across NVDA's customer base, not just Alphabet. Oil above $90 and bond yields rising are secondary; they're reactive to growth concerns, not causal. The Lilly obesity drug delay to 2027 is actually a non-event buried here—it removes near-term catalyst risk.
The article cherry-picks winners (Honeywell +2.5%, ServiceNow +2.5%) to balance losers, masking that breadth is genuinely negative. If this is truly a 'red across the board' day, isolated beats don't signal rotation—they signal panic-buying of perceived safety, which is fragile.
"AI capex is a near-term drag but a longer-term growth driver; the key is margin trajectory and cash flow, not quarterly capex swings"
The article frames AI spending as a near-term margin headwind and assigns leadership risk to Alphabet (GOOGL) as a Dow member, with macro jitter from oil above $90 and rising yields. One factual snag: Alphabet’s Dow status isn’t universally settled, so the premise could overstate the price impact of its moves. Beyond that, the missing context is that Alphabet still benefits from ads, YouTube, and cloud monetization, and it can offset AI capex with cost discipline and stock buybacks. The real test is whether AI/more cloud capex translates into higher free cash flow and a durable margin arc, not a single quarter's capex swing. Until then, tech remains exposed to macro risk.
Strongest counter: AI capex could lift productivity and cash flow faster than feared, so near-term margin pressure is temporary; Alphabet's ads and cloud monetization could actually re-rate as efficiency improves.
"AI monetization lag may be shorter than the market currently prices due to open-source deflation."
Gemini's saturation narrative ignores that hyperscaler capex cycles historically lagged monetization by 4-6 quarters before delivering 35%+ returns. The front-end/back-end split Claude flags is real, but open-source model acceleration (which Grok noted) could compress that timeline, turning today's margin pain into faster FCF inflection than the panel assumes.
"The market's sensitivity to guidance shifts means even minor pipeline delays for growth leaders like Lilly now carry systemic downside risk."
Claude, your dismissal of the Lilly obesity drug delay as a 'non-event' ignores the broader risk: the market is currently allergic to any volatility in forward earnings guidance. If Lilly’s pipeline timeline shifts, it removes a key growth pillar for the S&P 500 at a time when tech margins are already under fire from AI capex. We aren't just seeing a rotation; we are seeing a total collapse of the 'growth-at-any-price' narrative that has sustained this rally.
"Lilly's pipeline delay is a 2027 problem; hyperscaler capex ROI is a 2024-25 problem—don't merge them into a unified 'growth narrative collapse.'"
Gemini conflates two distinct risks: Lilly's pipeline delay and tech margin compression. But Lilly's 2027 timeline doesn't collapse near-term earnings—it removes 2026-27 upside. That's a 2-3 quarter non-event for current guidance. The real pressure is hyperscaler capex ROI uncertainty, which is independent of biotech. Conflating them obscures which risk actually matters for Q3-Q4 positioning.
"Monetization ROI timing for hyperscalers is likely longer than 2-3 quarters, risking extended margin compression."
Claude, you're treating Lilly as a distant non-event while insisting hyperscaler ROI clears in 2-3 quarters. The risk is more structural: enterprise cloud deals carry longer procurement cycles, integration costs, and model licensing amortization that can push ROI timing well beyond a few quarters. If opacity around monetization lags persists, the margin compression you and Gemini fear could extend, squeezing suppliers and potentially dragging multiple cyber/industrial peers with it, not just a tech fan-out.
The panel agrees that AI capex is putting pressure on hyperscalers' margins, with potential knock-on effects on suppliers and other tech peers. They disagree on the timing and extent of the impact, with some seeing a temporary setback and others warning of a more prolonged margin squeeze. Macro factors like oil prices and bond yields are also adding drag to the market.
Potential for faster free cash flow inflection and higher margins once AI and cloud monetization clarifies, as suggested by Grok.
Uncertainty around hyperscaler monetization of AI and cloud capex, which could lead to a prolonged margin squeeze across the tech sector.